Kathryn B. McKenzie's most recent trade in Neogenomics Inc. was a trade of 2,100 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 11, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neogenomics Inc. | Kathryn B. McKenzie | Chief Sustainability/Risk Ofcr | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jan 2022 | 2,100 | 17,900 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Kathryn B. McKenzie | Chief Sustainability/Risk Ofcr | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.07 per share. | 11 Jan 2022 | 2,100 | 49,361 (0%) | 0% | 9.1 | 19,047 | Common Stock |
| Neogenomics Inc. | Kathryn B. McKenzie | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2021 | 30,572 | 47,261 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Kathryn B. McKenzie | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2021 | 5,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Kathryn B. McKenzie | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.07 per share. | 21 Dec 2021 | 5,000 | 16,689 (0%) | 0% | 9.1 | 45,350 | Common Stock |
| Neogenomics Inc. | Kathryn B. McKenzie | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 21 Dec 2021 | 1,846 | 11,689 (0%) | 0% | 35 | 64,610 | Common Stock |
| Neogenomics Inc. | Kathryn B. McKenzie | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 35,171 | 35,171 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Kathryn B. McKenzie | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 6,207 | 13,535 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Kathryn B. McKenzie | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2021 | 432 | 7,328 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Kathryn B. McKenzie | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2021 | 169 | 7,760 (0%) | 0% | 0 | Common Stock |